DOCSLIB.ORG

Immunology and Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunology and Inflammation Immunology and Inflammation Inflammation is a critical, signal-mediated response to potential signs of danger and damage. While acute inflammation is important to the immune response, chronic, inappropriate inflammation can cause tissue destruction and lead to disease (e.g., allergies, autoimmune disorders). Cayman offers a wide range of tools to help you study the factors related to innate and adaptive immune responses. · Assays and mass spec standards for the quantification of bioactive lipids · Corticosteroid receptor agonists, mast cell stabilizers, and antihistamines · Tools to study citrullination and carbamylation · TLR and chemokine receptor modulators and NETosis assays LOOK INSIDE TO LEARN MORE · Immunopeptidome profiling services Page 1 mast cell allergen eosinophil target protein Inflammatory IgE Lipid Mediators PAD Page 2 cytokines citrullinated CysLTs cytokines protein Allergy & Asthma PGs CysLTs histamines ACPA Page 3 histones Autoimmunity neutrophil LL-37 NE MPO Page 4 · Immunotherapeutics LTB 4 · Adaptive Immunity receptor TLR T cell PAMPs Page 5 SPMs T cell Innate Immunity receptor MHC Page 7 COOH · Infectious Disease macrophage · Immunosuppressants DHA (DPA or EPA or AA) APC The cellular environment during infection (or allergen exposure), immune activation, and subsequent inflammation involves a highly complex and well-coordinated team of mediators. This includes mast cells that react to danger by releasing histamines, pro-inflammatory cytokines, and eicosanoids and neutrophils/eosinophils that respond to these signals with an antimicrobial arsenal that involves NETs. Certain protein modifications, like citrullination, can alter self-epitopes and elicit an autoantibody response via T cells. Professional APCs, such as macrophages, activate T cells by displaying a MHC. SPMs, byproducts of DHA and other fatty acids, are generated later to initiate the resolution of inflammation. 2019 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Inflammatory Lipid Mediators Cayman offers a wide range of tools to study biochemical mediators released during the inflammatory process. Our core business is built around the production of bioactive lipids, including the manufacture of high-purity lipid standards and assays for their measurement, as well as biochemicals to disrupt key eicosanoid mediator production or signaling. We lead the industry as a resource for prostaglandins, leukotrienes, and specialized pro-resolving mediators pertinent to the study of immune activation and inflammation. Leukotrienes Specialized Pro-Resolving Mediators Item No. Product Name Item No. Product Name 20110 Leukotriene B4 90410 Lipoxin A4 520111 Leukotriene B4 ELISA Kit* 590410 Lipoxin A4 ELISA Kit 120114 BLT 1 Receptor Polyclonal Antibody 90415 15(R)-Lipoxin A4 20210 Leukotriene C4 90420 Lipoxin B4 20310 Leukotriene D4 10878 Maresin 1 20410 Leukotriene E4 501150 Maresin 1 ELISA Kit 501060 Leukotriene E4 ELISA Kit 16369 Maresin 2 500390 Cysteinyl Leukotriene ELISA Kit* 17007 MCTR1 20001 Cysteinyl Leukotriene HPLC Mixture I 17008 MCTR2 20002 Cysteinyl Leukotriene HPLC Mixture II 19067 MCTR3 120500 CysLT 1 Receptor Polyclonal Antibody 19064 PCTR1 14713 CysLT 1 Receptor Polyclonal FITC Antibody 10010390 Protectin D1 10012554 Resolvin D1 Prostaglandins 13060 17(R)-Resolvin D1 Item No. Product Name 500380 Resolvin D1 ELISA Kit 501001 tetranor-PGDM ELISA Kit 10007279 Resolvin D2 12010 Prostaglandin D2 501120 Resolvin D2 ELISA Kit 512031 Prostaglandin D2 ELISA Kit* 13834 Resolvin D3 512011 Prostaglandin D2-MOX ELISA Kit* 13835 Resolvin D4 14010 Prostaglandin E2 10007280 Resolvin D5 314010 Prostaglandin E2-d4 18702 SPM D-series LC-MS Mixture 514010 Prostaglandin E2 ELISA Kit - Monoclonal* 10007848 Resolvin E1 516521 11β-Prostaglandin F2α ELISA Kit Common SPMs listed; methyl ester forms, internal standards, and LC-MS mixtures *Also available: express kits also available COOH COOH COOH COOH AA (90010) DPA (90165) DHA (90310) EPA (90110) www.caymanchem.com 45 -2 Request the full Specialized 15 5 2 15 COOH OOH COOH COOH COOH COOH OOH 18(R)-HpEPE *15(S)-HpETE (44720) *5(S)-HpETE (44230) OOH 5 HOO 13(R)-HpDPA OH 5 COOH OOH HOO 17(S)-HpDHA (13185) COOH OH Pro-Resolving Mediators wall poster at COOH 10(S),17(S)-DiHDHA (PDX) (10008128) COOH OOH *5(S),15(S)-DiHpETE COOH O COOH 18(R)-HEPE HO Resolvin E3 OH HO 13(R)-HDPA OH 16(S),17(S)-epoxy Protectin 5 O COOH O OH OH OH OH OOH NH OH COOH COOH COOH OH COOH www.caymanchem.com/Literature OH COOH HO H2N O S *5(S),6(S)-epoxy-15(S)-DiHETE COOH NH COOH OH Resolvin T4 (18440) COOH 5(S)-hydroperoxy- Resolvin T1 (18437) Resolvin E2 (13827) OH Protectin D1/Neuroprotectin D1 (10010390) OH PCTR1 (19064) 18(R)-HEPE OH HO OH OH OH OH COOH COOH COOH OH COOH OH H N H N 2 2 O OH OH COOH OH HO OH O S HOOC S HO OH OH COOH OH NH COOH COOH Lipoxin A4 (90410) Lipoxin B4 (90420) OH (15(R)-Lipoxin A4, 90415) COOH Resolvin E1 (10007848) Resolvin T2 (18438) Resolvin T3 (18439) PCTR2 (19065) Protectin Family PCTR3 (19066) OH 5(S),6(S)-epoxy- 18(R)-HEPE *Have not been shown to have pro-resolving properties in published literature E-Reso COOH HOO COOH 5 15 12 15 HOO 1 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108HO · USA · (800) 364-9897 17(S)-HpDHA (13185) WWW.CAYMANCHEM.COM 4(S)-hydroperoxy- 17(S)-HDHA 5 COOH O O HOO OH OOH O COOH COOH COOH COOH COOH HO 13(S),14(S)-epoxy-Maresin 14(S)-HpDHA 14(S),20(R)-DiHDHA (19139) HO 4(S),5(S)-epoxy- 7(S),8(S)-epoxy- 7(S)-hydroperoxy- 17(S)-HDHA HO 17(S)-HDHA HO 17(S)-HDHA O HOOC NH NH H HOOC 2 N S HO COOH O HOOC OH OH HO COOH HO OH OH HO COOH OH COOH COOH HO COOH OH MCTR1 (17007) OH HO HO HO OH HO OH Resolvin D3 (13834) Resolvin D4 (13835) Resolvin D2 (10007279) Resolvin D1 (10012554) Resolvin D5 (10007280) COOH NH COOH (17(R)-Resolvin D1, 13060) 2 Resolvin D6 (10484) H Hydrolase HOOC N S 14(S)-HDHA (15253) O OH OH OH COOH SPECIALIED PRO-RESOLING MEDIATORS Maresin 1 (10878) MCTR2 (17008) Soluble Epoxide The resolution of inflammation is an active process that is driven by unique signaling molecules. An important group of these specialized pro-resolving Hydrolase NH HO 2 mediators (SPMs) is derived from polyunsaturated fatty acids (arachidonic acid (AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and S docosahexaenoic acid (DHA)) that are liberated during the inflammatory process. Studies have demonstrated that these SPMs, which include resolvins, HOOC OH lipoxins, maresins, and protectins, evoke cellular and tissue responses that help conclude an inflammatory episode. Moreover, the addition of nanomolar OH COOH COOH concentrations of SPMs to an inflammatory milieu can have profound effects, such as reducing leukocyte infiltration, enhancing phagocytosis, and OH OH Maresin 2 (16369) MCTR3 (19067) reducing pain. Cayman Chemical, a leader in the synthesis of lipid mediators, offers an array of SPMs to help make your research possible. COOH 14(S),21(R)-HDHA Allergy & Asthma Immune activation and inflammation are both characteristics of an allergic or asthmatic response. Cayman’s line of allergy and asthma research products includes tools for measuring and disrupting eicosanoid mediators and assays to assess ovalbumin-induced immune responses. Key corticosteroid receptor agonists, mast cell stabilizers, histamine receptor antagonists/inverse agonists, phosphodiesterase inhibitors, and β-adrenergic receptor agonists are also available. DiHOMEs: Potential drivers of allergic responses and thermogenic activity Dihydroxy metabolites of linoleic acid may be biomarkers (±)9(10)-DiHOME ELISA Kit for the development of asthma and important mediators Item No. 501710 of fatty acid metabolism. Cayman offers competitive ELISAs to quantify 9(10)-DiHOME and 12(13)-DiHOME (±)12(13)-DiHOME ELISA Kit in plasma and serum. Item No. 501720 Corresponding unlabeled and deuterated standards for EpOMEs and DiHOMEs are also available for quantification by mass spec Ovalbumin Assay Kits β-Adrenergic Receptor Agonists Item No. Product Name Item No. Product Name 500840 Anti-Ovalbumin IgE (mouse) ELISA Kit 14985 Clenbuterol (hydrochloride) 500830 Anti-Ovalbumin IgG1 (mouse) ELISA Kit 15584 Formoterol (hemifumarate) 16009 Salmeterol (xinafoate) Corticosteroid Receptor Agonists Over 10 β-adrenergic receptor agonists available online Item No. Product Name Antihistamines 15407 Budesonide Item No. Product Name 20739 Hydrocortisone 16967 Astemizole 18026 Triamcinolone acetonide 14637 Clemastine (fumarate) Over 10 corticosteroid receptor agonists available online 15625 Loratadine Mast Cell Stabilizers 14615 Meclizine (hydrochloride) Item No. Product Name Over 30 histamine receptor antagonists and/or inverse agonists available online 22173 Compound 48/80 (hydrochloride) 21379 Cromolyn (sodium salt hydrate) Conveniently Detect Histamine 23994 Lodoxamide Histamine EIA Kit - Item No. 589651 Phosphodiesterase Inhibitors · Measure histamine in plasma, serum, Item No. Product Name bronchoalveolar lavage, tissue extracts, and 14832 Ibudilast cell culture supernatant samples 15141 Roflumilast · Assay 33 samples in duplicate 10011132 Rolipram · Incubation: Overnight 10008671 Sildenafil Manufactured by Bertin Bioreagent Over 10 PDE inhibitors as well as related adenosine receptor antagonists available online WWW.CAYMANCHEM.COM CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 2 Autoimmunity Autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus, are tied to post-translational modifications
Load more

Recommended publications
  • SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M
    SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab)
    [Show full text]
  • What Lessons Can We Learn from 20 Years of Chemokine T D Di ? Receptor
    What lessons can we learn from 20 years of chemokine receptdtor drug discovery? John G. Cumming, PhD 5th RSC / SCI symposium on GPCRs in Medicinal Chemistry 15th-17th September 2014, Actelion, Allschwil, Basel, Switzerland Outline Background: chemokines and their receptors Chemokine receptor drug discovery and development Emerging opportunities for chemokine drug discovery Conclusions and learning Chemokines and chemokine receptors CXC(α) • Chemokines (chemoattractant cytokines) are 70-120 aa proteins • 44 chemokines in 4 major families and 22 chemokine receptors in human genome • ‘Cell positioning system’ in the body • Many receptors bind multiple ligands • Many ligands bind multiple receptors Chemotaxis Human monocytes + CCL2 (red) Volpe et al. PLoS ONE 2012, 7(5), e37208 CCR2 antagonists inhibit chemotaxis and infiltration Vasculature CCL2 release Spinal or Peripheral Tissue Recruited monocyte Site of CCL2 release CCR2 antagonists inhibit chemotaxis and infiltration CCR2 antagonist Circulating monocyte CCL2 release CCL2 release from peripheral injury site or central PAF terminals Role of chemokine system in pathophysiology • Potential role in inflammatory and autoimmune diseases: Multiple sclerosis, Rheumatoid arthritis, COPD, allergic asthma, IBD, psoriasis - Expression levels of chemokines and receptors in relevant tissues and organs of patients and animal disease models - Mouse knockout ppyphenotype in disease models • Established role in HIV infection Katschke et al., 2001 Arthritis Rheum, 44, 1022 - CCR5 and CXCR4 act as HIV-1
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]
  • Mozobil (Plerixafor Injection) AHM
    Mozobil (Plerixafor Injection) AHM Clinical Indications • Mozobil (Plerixafor Injection) in combination with granulocyte-colony stimulating factor (G-CSF) is considered medically necessary to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation for patients who have failed a prior mobilization attempts with G-CSF with 1 or more of the following conditions o Lymphoma (i.e., Hodgkin's disease and non-Hodgkin's lymphoma) o Multiple myeloma o Germ cell tumors o WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome • Current role remains uncertain. Based on review of existing evidence, there are currently no clinical indications for this technology. See Inappropriate Uses for more detailed analysis of the evidence base. Mozobil is considered investigational for all other indications Evidence Summary • Background • There has been a steady rise in the use of peripheral blood stem cells (PBSC) as a source of hematopoietic stem cells. In general, less than 0.05 % of white blood cells (WBC) are CD34+ cells. Chemotherapy results in a 5- to 15-fold increase of PBSC. Chemotherapy in combination with growth factors increases CD34+ cells up to 6 % of WBC. In the allogeneic setting, granulocyte-colony stimulating factor (G-CSF) is used alone for mobilization of PBSC. Several factors affect PBSC mobilization; including age, gender, type of growth factor, dose of the growth factor, and in the autologous setting, the patient's diagnosis, chemotherapy regimen and number of previous chemotherapy cycles or radiation. Muscle and bone pain are common side effects in allogeneic stem cell mobilization, but are usually tolerated with the use of analgesics.
    [Show full text]
  • Macrophages in Nonalcoholic Steatohepatitis: Friend Or Foe?
    Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe? Authors: Joel Grunhut,1 Wei Wang,1 Berk Aykut,1 Inderdeep Gakhal,1 Alejandro Torres-Hernandez,1 *George Miller1,2 1. S.A. Localio Laboratory, Department of Surgery, New York University School of Medicine, New York City, New York, USA 2. Department of Cell Biology, New York University School of Medicine, New York City, New York, USA *Correspondence to [email protected] Disclosure: The authors have declared no conflicts of interest. Received: 14.11.17 Accepted: 28.02.18 Keywords: Inflammation, macrophage, steatohepatitis. Citation: EMJ Hepatol. 2018;6[1]:100-109. Abstract Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease that is characterised by steatosis, chronic inflammation, and hepatocellular injury with or without fibrosis. The role and activation of macrophages in the pathogenesis of NASH is complex and is being studied for possible therapeutic options to help the millions of people diagnosed with the disease. The purpose of this review is to discuss the pathogenesis of NASH through the activation and role of Kupffer cells and other macrophages in causing inflammation and progression of NASH. Furthermore, this review aims to outline some of the current therapeutic options targeting the pathogenesis of NASH. INTRODUCTION The progression to NASH from its less severe form of NAFLD can be predicted by the amount of inflammation present in hepatic tissue.2 Nonalcoholic steatohepatitis (NASH), a subtype Severe inflammation can contribute to the of nonalcoholic fatty liver disease (NAFLD), is progression of other liver diseases, such as one of the most prevalent ongoing liver diseases cirrhosis, fibrosis, and hepatocellular carcinoma.
    [Show full text]
  • Documents Numérisés Par Onetouch
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01) N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01) A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01) 21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): 72 US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US) 24 Délivré le : 27/09/2018 74 Mandataire: GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018 54 Titre: Toll like receptor modulator compounds. 57 Abrégé : The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18435 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
    [Show full text]
  • Combined Phytochemistry and Chemotaxis Assays For
    Combined Phytochemistry and Chemotaxis Assays for Identification and Mechanistic Analysis of Anti-Inflammatory Phytochemicals in Fallopia japonica Ming-Yi Shen, Yan-Jun Liu, Ming-Jaw Don, Hsien-Yueh Liu, Zeng-Weng Chen, Clément Mettling, Pierre Corbeau, Chih-Kang Chiang, Yu-Song Jang, Tzu-Hsuan Li, et al. To cite this version: Ming-Yi Shen, Yan-Jun Liu, Ming-Jaw Don, Hsien-Yueh Liu, Zeng-Weng Chen, et al.. Combined Phy- tochemistry and Chemotaxis Assays for Identification and Mechanistic Analysis of Anti-Inflammatory Phytochemicals in Fallopia japonica. PLoS ONE, Public Library of Science, 2011, 6 (11), pp.e27480. 10.1371/journal.pone.0027480. hal-00645719 HAL Id: hal-00645719 https://hal.archives-ouvertes.fr/hal-00645719 Submitted on 25 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Combined Phytochemistry and Chemotaxis Assays for Identification and Mechanistic Analysis of Anti- Inflammatory Phytochemicals in Fallopia japonica Ming-Yi Shen1, Yan-Jun Liu1,2, Ming-Jaw Don3, Hsien-Yueh Liu4, Zeng-Weng Chen1, Cle´ment Mettling5, Pierre Corbeau5, Chih-Kang Chiang6, Yu-Song Jang1, Tzu-Hsuan Li1, Paul Young1, Cicero L.
    [Show full text]
  • Standard Specialty PA and QL List January 2015
    Standard Specialty PA and QL List January 2015 Standard PA or PA with QL Programs Therapeutic Category Drug Name Quantity Limit Anti-infectives Antiretrovirals, Hepatitis B BARACLUDE (entecavir) 1 tab/day BARACLUDE (entecavir) Soln 630 ml/30days HEPSERA (adefovir) 1 tab/day TYZEKA (telbivudine ) 1 tab/day Antiretrovirals, HIV FUZEON (enfuvirtide) 60 vials or 1 kit/30 days SELZENTRY (maraviroc) None TRUVADA (emtricitabine/tenofovir) None Cardiology Antilipemic JUXTAPID (lomitapide) 20 mg 3 tabs/day JUXTAPID (lomitapide) 5 mg, 10 mg 1 tab/day KYNAMRO (mipomersen) 4 syringes/28 days Pulmonary Arterial Hypertension ADCIRCA (tadalafil) 2 tabs/day ADEMPAS (riociguat) 90 tabs/30 days FLOLAN (epoprostenol) None LETAIRIS (ambrisentan) 1 tab/day OPSUMIT (macitentan) 1 tab/day ORENITRAM (treprostinil diolamine) None REMODULIN (treprostinil) None REVATIO (sildenafil) 3 tabs or vials/day TRACLEER (bosentan) 2 tabs/day TYVASO (treprostinil) 1 ampule/day VELETRI (epoprostenol) None VENTAVIS (iloprost) 9 ampules/day Vasopressors NORTHERA (droxidopa) None Central Nervous System Anticonvulsants SABRIL (vigabatrin) None Depressant XYREM (sodium oxybate) 3 bottles (540 mL)/30 days Neurotoxins BOTOX (onabotulinumtoxinA) None DYSPORT (abobotulinumtoxinA) None MYOBLOC (rimabotulinumtoxinB) None XEOMIN (incobotulinumtoxinA) None Parkinson's APOKYN (apomorphine) None Sleep Disorder HETLIOZ (tasimelteon) 1 cap/day Dermatology Alkylating Agents VALCHLOR (mechlorethamine) Gel None Endocrinology & Metabolism Gonadotropins ELIGARD (leuprolide) 22.5 mg (3-month) 1
    [Show full text]
  • Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3
    1521-0111/96/6/753–764$35.00 https://doi.org/10.1124/mol.119.116954 MOLECULAR PHARMACOLOGY Mol Pharmacol 96:753–764, December 2019 Copyright ª 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. Special Section: From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function – Minireview Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3 Vladimir Bobkov, Marta Arimont, Aurélien Zarca, Timo W.M. De Groof, Bas van der Woning, Hans de Haard, and Martine J. Smit Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (V.B., M.A., A.Z., T.W.M.D.G., M.J.S.); and argenx BVBA, Zwijnaarde, Belgium (V.B., B.W., H.H.) Downloaded from Received April 22, 2019; accepted July 3, 2019 ABSTRACT Dysregulation of the chemokine system is implicated in a number CXCR4 and ACKR3, formerly referred to as CXCR7. We of autoimmune and inflammatory diseases, as well as cancer. discuss their unique properties and advantages over small- molpharm.aspetjournals.org Modulation of chemokine receptor function is a very promising molecule compounds, and also refer to the molecules in approach for therapeutic intervention. Despite interest from preclinical and clinical development. We focus on single- academic groups and pharmaceutical companies, there are domain antibodies and scaffolds and their utilization in GPCR currently few approved medicines targeting chemokine recep- research. Additionally, structural analysis of antibody binding tors. Monoclonal antibodies (mAbs) and antibody-based mole- to CXCR4 is discussed. cules have been successfully applied in the clinical therapy of cancer and represent a potential new class of therapeutics SIGNIFICANCE STATEMENT targeting chemokine receptors belonging to the class of G Modulating the function of GPCRs, and particularly chemokine protein–coupled receptors (GPCRs).
    [Show full text]
  • A Highly Selective and Potent CXCR4 Antagonist for Hepatocellular Carcinoma Treatment
    A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment Jen-Shin Songa,1, Chih-Chun Changb,1, Chien-Huang Wua,1, Trinh Kieu Dinhb, Jiing-Jyh Jana, Kuan-Wei Huangb, Ming-Chen Choua, Ting-Yun Shiueb, Kai-Chia Yeha, Yi-Yu Kea, Teng-Kuang Yeha, Yen-Nhi Ngoc Tab, Chia-Jui Leea, Jing-Kai Huanga, Yun-Chieh Sungb, Kak-Shan Shiaa,2, and Yunching Chenb,2 aInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China; and bInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China Edited by Michael Karin, University of California San Diego, La Jolla, CA, and approved February 4, 2021 (received for review July 23, 2020) The CXC chemokine receptor type 4 (CXCR4) receptor and its ligand, advanced HCC (9, 17), the concept of which has been experimentally CXCL12, are overexpressed in various cancers and mediate tumor validated by the discovery of a CXCR4 antagonist, BPRCX807. progression and hypoxia-mediated resistance to cancer therapy. AMD3100 was the first Food and Drug Administration (FDA)- While CXCR4 antagonists have potential anticancer effects when approved CXCR4 antagonist used for peripheral blood stem cell combined with conventional anticancer drugs, their poor potency transplantation (PBSCT) (18); however, its application to solid against CXCL12/CXCR4 downstream signaling pathways and sys- tumors is limited by its poor pharmacokinetics and toxic adverse temic toxicity had precluded clinical application. Herein, BPRCX807, effects after long-term administration (19, 20). Thus, a CXCR4 known as a safe, selective, and potent CXCR4 antagonist, has been antagonist with higher safety and better pharmacological and designed and experimentally realized.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,670,205 B2 Aktoudianakis Et Al
    USOO9670205B2 (12) United States Patent (10) Patent No.: US 9,670,205 B2 Aktoudianakis et al. (45) Date of Patent: Jun. 6, 2017 (54) TOLL LIKE RECEPTOR MODULATOR FOREIGN PATENT DOCUMENTS COMPOUNDS EP 042593 A1 12, 1981 EP O322133 A1 6, 1989 (71) Applicant: Gilead Sciences, Inc., Foster City, CA EP 404355 A1 12, 1990 (US) JP 2000038350 A 2, 2000 JP 2000053.653. A 2, 2000 JP 2000053654 A 2, 2000 (72) Inventors: Evangelos Aktoudianakis, Redwood WO WO-9307124 A1 4f1993 City, CA (US); Gregory Chin, San WO WO-9427439 A1 12, 1994 Francisco, CA (US); Richard L. WO WO-0121619 A1 3, 2001 Mackman, Millbrae, CA (US); Samuel WO WO-03001887 A2 1, 2003 WO WO-2006050843 A1 5, 2006 E. Metobo, Newark, CA (US); Michael WO WO-2006069805 A2 T 2006 R. Mish, Foster City, CA (US); WO WO-2006135993 A1 12/2006 Hyung-jung Pyun, Fremont, CA (US); WO WO-2007093901 A1 8, 2007 Jeff Zablocki, Los Altos, CA (US) WO WO-2008OO97O6 A1 1, 2008 WO WO-2008O3O455 A2 3, 2008 WO WO-2008077649 A1 T 2008 (73) Assignee: GILEAD SCIENCES, INC., Foster WO WO-2008077651 A1 T 2008 City, CA (US) WO WO-2008154221 A2 12/2008 WO WO-2009003669 A2 1, 2009 (*) Notice: Subject to any disclaimer, the term of this WO WO-201OOO2998 A1 1, 2010 patent is extended or adjusted under 35 WO WO-2010O42489 A2 4/2010 WO WO-2O10046639 A1 4/2010 U.S.C. 154(b) by 0 days. WO WO-2010092340 A1 8, 2010 WO WO-2011057148 A1 5, 2011 (21) Appl.
    [Show full text]
  • Potential New Therapeutic Agents: Effects on HIV Replication and Viral Escape
    Departament de Biologia Cel·lular, de Fisiologia i d’Immunologia Universitat Autònoma de Barcelona Potential New Therapeutic Agents: Effects on HIV Replication and Viral Escape Gemma Moncunill Piñas Laboratori de retrovirologia Fundació irsiCaixa Hospital Universitari Germans Trias i Pujol Memòria de la tesi presentada per obtenir el grau de Doctora en Immunologia per la Universitat Autònoma de Barcelona Bellaterra, 2 de desembre del 2008 Director: Dr. José A. Esté Tutora: Dra. Paz Martínez Amb el suport del Departament d’Educació i Universitats de la Generalitat de Catalunya Laboratori de Retrovirologia Hospital Universitari Germans Trias i Pujol El Dr. José A. Esté, Investigador Sènior del Laboratori de Retrovirologia de la Fundació irsiCaixa de l’Hospital Universitari Germans Trias i Pujol de Badalona, Certifica: Que el treball experimental i la redacció de la memòria de la Tesi Doctoral titulada “Potential New Therapeutic Agents: Effects on HIV replication and Viral Escape” han estat realitzades per la Gemma Moncunill Piñas sota la seva direcció i considera que és apta per ser presentada per optar al grau de Doctora en Immunologia per la Universitat Autònoma de Barcelona. I per tal que en quedi constància, signa aquest document a Badalona, el 2 de desembre del 2008. Dr. José A. Esté La Dra. Paz Martínez Ramírez, Coordinadora de Tercer Cicle de Biologia Cel·lular, Fisiologia i Immunologia de la Universitat Autònoma de Barcelona, Certifica: Que el treball experimental i la redacció de la memòria de la Tesi Doctoral titulada “Potential New Therapeutic Agents: Effects on HIV replication and Viral Escape” han estat realitzades per la Gemma Moncunill Piñas sota la seva tutoria i considera que és apta per ser presentada per optar al grau de Doctora en Immunologia per la Universitat Autònoma de Barcelona.
    [Show full text]